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A B S T R A C T
Background: Myoclonus-dystonia (M-D) due to a pathogenic variant of SGCE is an autosomal dominant inherited
movement disorder. Apart from motor symptoms, psychiatric disorders are highly prevalent in patients with M-
D. Previous studies suggest, but never tested directly, that the type of psychiatric disorder differs between
dystonia syndromes, probably related to disease specific pathology. Little is known about other non-motor
symptoms (NMS) in M-D. Here, we systematically study NMS in M-D in direct comparison to other types of
dystonia and healthy controls.
Methods: Standardized questionnaires were used to assess type and severity of psychiatric co-morbidity, sleep
problems, fatigue and quality of life. Results of M-D patients with a pathogenic variant of SGCE were compared
to results of idiopathic cervical dystonia (CD) patients, dopa-responsive dystonia (DRD) patients with a patho-
genic variant of GCH1 and controls.
Results: We included 164 participants: 41M-D, 51 CD, 19 DRD patients, 53 controls. Dystonia patients (M-D, CD
and DRD) had an increased prevalence of psychiatric disorders compared to controls (56–74% vs. 29%). In M-D
we found a significantly increased prevalence of obsessive-compulsive disorder (OCD) and psychosis compared
to CD and DRD. All dystonia patients had more sleep problems (49–68% vs. 36%) and fatigue (42–73% vs. 15%)
than controls. Compared to other dystonia subtypes, M-D patients reported less excessive daytime sleepiness and
fatigue.
Conclusion: Psychiatric comorbidity is frequent in all dystonia types, but OCD and psychosis are more common
in M-D patients. Further research is necessary to elucidate underlying pathways.
1. Introduction
Myoclonus-dystonia (M-D) is a rare hyperkinetic movement dis-
order. About 50% of the patients have a known pathogenic variant in
the epsilon-sarcoglycan gene (SGCE), which has an autosomal domi-
nant inheritance pattern with maternal imprinting [1]. Symptoms
usually start in the first or second decade of life. The typical clinical
picture is that of a relatively mild dystonia in the hands (writer's cramp)
and neck, and more pronounced myoclonus in the upper body which is
alcohol responsive [2].
Apart from the motor symptoms, non-motor symptoms (NMS),
especially psychiatric disorders, are highly prevalent in patients with
M-D. A large international study and other smaller studies showed a
higher incidence of social phobias, alcohol dependence and obsessive
compulsive disorder (OCD) in M-D patients [3–5].
In other types of dystonia, both focal and generalized forms, psy-
chiatric features are also common. Previous studies suggest that the
type of psychiatric disorder differs between dystonia subtypes: de-
pression is the main psychiatric disorder in early-onset generalized
torsion dystonia, X-linked dystonia parkinsonism and dopa-responsive
dystonia (DRD); anxiety disorders in focal dystonias; substance abuse
and psychotic disorders in rapid-onset dystonia-parkinsonism [6,7].
However, each of these studies focused on one specific type of dystonia,
and results are difficult to compare due to differences in methodology.
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In addition to the psychiatric disorders, other NMS that are pre-
valent in dystonia are sensory abnormalities, pain, sleep disorders, a
high level of fatigue and cognitive problems. In general, patients with
dystonia have a higher frequency of all these NMS, but there are no
studies focusing on non-psychiatric NMS in M-D patients. It is important
to note that NMS have a considerable influence on the quality of life
(QoL) of dystonia patients [8]. Some studies show that NMS have a
larger impact on the QoL than the motor symptoms, highlighting the
burden of NMS.
Nowadays, the NMS are considered to be part of dystonia pheno-
types rather than secondary to the social effect of living with a chronic
movement disorder. The high prevalence of NMS in dystonia patients
before the onset of motor symptoms supports this hypothesis [7]. Fur-
thermore, lack of association between the severity of the psychiatric
symptoms and the severity of motor symptoms in both cervical dystonia
and generalized dystonia decreases the likelihood that NMS are a sec-
ondary effect of the motor symptoms [9,10]. If NMS are part of the
phenotype and therefore share a pathophysiological pathway with the
motor symptoms, we hypothesize that specific types of dystonia are
associated with specific NMS.
In this report, we performed a systematic assessment of psychiatric
features, sleep disorders and fatigue in M-D and compared these to a
group of normal controls without dystonia and two other types of
dystonia that are of special interest: idiopathic cervical dystonia (CD)
and DRD. Dystonia of the neck is one of the predominant features of M-
D. Although the age of onset in CD is later, the social impact and vis-
ibility for the environment are similar. DRD is a group of inherited
disorders due to a defect in the synthesis of dopamine. In this study we
chose to include only the most common DRD type which is caused by an
autosomal dominant inherited pathogenic variant in the GCH1 gene.
Although not entirely correct, this form of DRD will be referred to as
DRD in the rest of this article. It is suggested that NMS are part of the
phenotype in DRD. The similar age of onset and comparable severity of
symptoms, which usually do not lead to loss of independence, make
DRD patients a suitable control group.
Establishing which NMS are most prevalent in different dystonia
syndromes may shed light on the pathophysiology of the NMS.
Furthermore, more insight in NMS in different types of dystonia allows
for better personalized treatment and thereby improvement of QoL for
dystonia patients.
2. Methods
2.1. Study population
M-D patients with a confirmed pathogenic variant in the SGCE gene
were included. Data of three control groups were used: 1) clinically
confirmed isolated CD patients, 2) DRD patients with a confirmed pa-
thogenic variant in the GCH1 gene, 3) controls without a movement
disorder (results were previously reported [8,9,11]). All participants
were adults (age≥18 years). Exclusion criteria were the presence of
other neurological conditions or treatment with deep brain stimulation.
In addition, healthy participants with relatives with dystonia and, due
to exclusion criteria of the previous study [8,11], CD patients using
antidepressant treatment were excluded. Patients were recruited in
several Dutch hospitals and via the dystonia patient association, some
M-D patients were also recruited from Belgium. Controls were ac-
quaintances of patients or investigators or were recruited by adver-
tisements. Informed consent was obtained from all participants and the
study was approved by the medical ethics committee of the University
Medical Center Groningen (METc 2014/034).
2.2. Clinical characteristics, NMS and QoL
Clinical and demographic characteristics of the patients were ob-
tained by a standardized interview. Information about the duration of
dystonia and medication regimen were recorded. A standardized vi-
deotaped examination was performed in all patients. The severity of the
motor symptoms was scored by two independent experts. The 7-point
Clinical Global Impression Scale (CGI-S) was used to score motor se-
verity in all patients [12]. In M-D, severity of dystonia was assessed
with the Burke Fahn Marsden Dystonia Rating Scale (BFMDRS) [13],
and severity of myoclonus with an abbreviated version of the Unified
Myoclonus Rating Scale (UMRS) [14]. In the CD group the severity of
the torticollis was assessed with the Toronto Western Spasmodic Tor-
ticollis Rating Scale (TWSTRS) [15]. In the DRD group the BFMDRS was
used to assess severity of dystonia. The presence of psychiatric dis-
orders, including substance and alcohol abuse, as defined in the Diag-
nostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-
IV), was evaluated with the Mini International Neuropsychiatric In-
terview – PLUS (MINI-PLUS) [16]. The severity of current depressive,
anxious and obsessive compulsive symptoms were assessed with re-
spectively the Beck Depression Inventory (BDI), the Beck Anxiety In-
ventory (BAI) and the Yale Brown Obsessive Compulsive Scale (YBOCS)
[17–19]. Impaired sleep quality was assessed with the Pittsburgh Sleep
Quality Index (PSQI), excessive daytime sleepiness with the Epworth
Sleepiness Scale (ESS) and fatigue was assessed with the Fatigue Se-
verity Scale (FSS) [20–22]. The RAND-36 item Health Survey (RAND-
36) was used to assess the QoL [23]. More information and cut-off
values of the questionnaires can be found in Supplementary Table 1.
2.3. Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics version
23. A p-value<0.05 was considered statistically significant. All base-
line data were quantitatively described. A pairwise deletion of missing
data was used.
Fisher-Freeman-Halton exact tests were performed to compare the
presence of a DSM-IV diagnosis between respectively all groups and the
three patient groups. For variables which showed a significant differ-
ence between the patient groups post hoc analysis were performed
using a Bonferroni corrected p-value.
One way ANOVA, or in case of non-normality Kruskal Wallis test,
was performed to compare the psychiatric, sleep and QoL scales be-
tween all groups and the three patient groups. Post-hoc analysis with
Bonferroni correction of the p-values was performed for the variables
which showed a significant difference. The scores on the domains of the
RAND36 were combined into a mental health component and a phy-
sical health component using factor analysis as described previously.
We performed a correlation analysis to assess the association of age
of onset with the presence of psychiatric co-morbidity. Next, logistic
regression was performed on the variables with a p-value of< 0.05 in
the correlation analysis. Odds ratios with and without age at onset as
covariate were compared. To assess the influence of motor symptoms
on having a psychiatric disorder a binary logistic regression analysis
was performed.
Associations between QoL and clinical characteristics were assessed
using correlation analysis. With multivariate regression analysis, we
determined the influence of the variables with a p < 0.05 in the uni-
variate correlation analysis. Assumptions of normality, multi-
collinearity and homoscedasticity of the multivariate regression ana-
lysis were checked.
3. Results
We included 164 participants: 41M-D patients, 51 CD patients, 19
DRD patients, and 53 controls. The mean age was 49 years (range
22–75 years) in M-D patients, 54 years (range 20–80) in CD patients, 51
years (range 22–77) in DRD patients, and 53 years (range 20–83) in
controls. No significant differences in age and gender were found be-
tween groups. Age of onset was significantly higher in CD patients (43
years, range 18–70) than in M-D patients (6 years, range 0–50) and
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DRD patients (7 years, range 1–20). Clinical characteristics are de-
scribed in Table 1.
Nine patients with M-D were treated with medication, most often
with clonazepam (n=6), but also treatment with levetiracetam
(n=2), trihexyphenidyl or valproate acid (both n=1) was reported.
Almost all CD patients (n= 47) received botulinum toxin injections and
most DRD patients (n=17) were on levodopa treatment. Six M-D pa-
tients received antidepressant treatment with paroxetine (n= 3), ven-
lafaxine (n= 2) or escitalopram (n= 1). None of the CD patients and
controls received treatment with antidepressants. Three DRD patients
were on treatment with either mirtazapine (n= 2) or paroxetine
(n=1).
3.1. Psychiatry
Dystonia patients had visited their family doctor or mental health
care professional due to mental problems significantly more often
compared to controls (dystonia patients 65% (M-D=68%, CD=65%,
DRD=58%) vs. controls 35%; p= 0.01). Accordingly, 56% of the M-D
patients met the criteria of any psychiatric disorder according to the
DSM-IV at any point in their lives, which was comparable to the pre-
valence in CD (65%) and DRD (74%) patients versus a prevalence of
29% in the controls (p < 0.01) (Table 2).
The prevalence of almost all studied DSM-IV diagnoses were sig-
nificantly different between the four groups (Table 2). When the results
of M-D patients were compared to the other two dystonia groups, a
significant difference was found in the presence of obsessive compulsive
disorder (OCD) (M-D=20%, CD=2% and DRD=11%, p= 0.01),
generalized anxiety (M-D=5%, CD=12% and DRD=47%,
p=0.00), and psychosis (M-D=10%, CD=0% and DRD=0%,
p=0.03). Post hoc analysis showed significantly more OCD in M-D
patients compared to CD patients (p=0.03). Moreover, there was a
higher prevalence of generalized anxiety in the DRD group compared to
the M-D (p= 0.00) and CD patients (p=0.01).
To rule out any biases due to age at onset, we performed a corre-
lation analysis to assess the association of this variable with the pre-
sence of psychiatric co-morbidity (Supplementary Table 2). Next, lo-
gistic regression was performed on the variables with a p-value
of< 0.05 in the correlation analysis. Odds ratios with and without age
at onset as covariate were compared. Results show that the age of onset
of motor symptoms had an influence on the odds ratio of panic disorder
and OCD between CD and DRD, and CD and M-D patients, meaning that
age of onset might have some influence on our significant finding of
more OCD in the M-D group (odds ratio: 0.083, p=0.02 vs. odds ratio
with age of onset as covariate: 0.218, p=0.40) (Supplementary
Table 3). We assessed whether motor symptom characteristics (severity,
duration of dystonia, age of diagnosis, or duration of levodopa treat-
ment) predict the presence of a psychiatric disorder. We found no sig-
nificant association between motor characteristics and presence of a
psychiatric disorder (Supplementary Table 4).
Scores reflecting the severity of depression and anxiety were sta-
tistically different between the four groups (both p < 0.01), but were
not significantly different between the patient groups (p= 0.07 and
p=0.27) (Table 3). No differences were found in the scores concerning
severity of OCD.
3.2. Sleep and fatigue
In M-D, almost half of the patients subjectively reported to have
sleep problems (49%) and in CD and DRD sleep problems were even
more common (resp. 61% and 68%). This was significantly different
compared to controls (36%, p=0.04). A large proportion (42%) of the
M-D patients, 73% of the CD and 58% of the DRD patients reported that
they were more easily fatigued than their peers. This is a significantly
Table 1
Clinical characteristics of participants.
M-D n=41 CD n=51 DRD n=19 p-value Controls n=53 p-value
Age 48.7 (15.7) 54.2 (10.6) 51.1 (15.6) 0.148 53.4 (12.9) 0.204
Gender M/F 20/21 15/36 5/14 0.098 16/37 0.151
Age of onset 5.5 (0–60) 43 (18–70) 7 (1–20) 0.000**
Disease duration 45 (7–73) 10 (1–52) 40 (18–71) 0.000**
Video rating
BFMDRS 5.4 (5.2) 6.9 (5.4)
UMRS 13.8 (16.5)
TWSTRS 14.1 (4.8)
CGI-S 2.1 (1.3) 3.9 (1.4) 1.9 (0.6)
One way anova, kruskal wallis test and fisher-freeman-halton exact test were performed to compare the three patient groups and all four groups. BFMDRS:Burke Fahn
Marsden Dystonia Rating Scale; UMRS:Unified Myoclonus Rating Scale; TWSTRS:Toronto Western Spasmodic Torticollis Rating Scale; CGI-S: Clinical Global
Impression Scale M-D:myoclonus-dystonia; CD:cervical dystonia; DRD:dopa-responsive dystonia., **p < 0.01.
Table 2
Prevalence of psychiatric diagnoses according to the DSM IV assessed using the MINI PLUS.
M-D n= 41 CD n= 51 DRD n= 19 p-value Controls n= 51 p-value
Any psychiatric disorder 23 (56%) 33 (65%) 14 (74%) 0.411 15 (29%) 0.001**
Depressive disorder 15 (37%) 16 (31%) 8 (42%) 0.673 7 (14%) 0.024*
Generalized anxiety 2 (5%) 6 (12%) 9 (47%) 0.000** 0 (0%) 0.000**
Panic disorder 13 (32%) 6 (12%) 4 (21%) 0.061 1 (2%) 0.000**
Agoraphobia 12 (29%) 12 (24%) 8 (42%) 0.309 1 (2%) 0.000**
Social phobia 5 (12%) 9 (18%) 4 (21%) 0.579 0 (0%) 0.003**
Specific phobia 7 (17%) 8 (16%) 3 (16%) 1.000 2 (4%) 0.122
OCD 8 (20%) 1 (2%) 2 (11%) 0.014* 0 (0%) 0.000**
Psychosis 4 (10%) 0 (0%) 0 (0%) 0.032* 0 (0%) 0.009**
Dysthymia 1 (2%) 4 (8%) 1 (5%) 0.554 0 (0%) 0.144
Hypomania 4 (10%) 2 (4%) 2 (11%) 0.432 0 (0%) 0.056
Alcohol dependence 3 (7%) 2 (4%) 1 (5%) 0.857 3 (6%) 0.960
Values are presented as number (percentage%). Fisher-Freeman-Halton exact tests were performed to compare the three patient groups and all four groups.
OCD:obsessive compulsive disorder; M-D:myoclonus-dystonia; CD:cervical dystonia; DRD:dopa-responsive dystonia. *p < 0.05, **p < 0.01.
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higher percentage than in the controls (15%, p=0.00).
The scores on all questionnaires about sleep disturbances and fa-
tigue were higher in the dystonia group compared controls (Table 3).
Moreover, the scores reflecting excessive daytime sleepiness (ESS) and
quality of sleep (PSQI) differed significantly between patient groups.
Post hoc analysis showed significantly more excessive daytime sleepi-
ness and a worse quality of sleep in DRD compared to M-D patients
(p=0.03 and p=0.02).
In M-D, mean scores on the questionnaires concerning sleep and
fatigue were not, or only marginally, above the clinical cut-off value
(ESS=7.3, cut-off=10; PSQI=5.9, cut-off= 5; FSS=35, cut-
off= 36) and only the score indicating fatigue was significantly higher
compared to controls (p= 0.00).
3.3. Quality of life
The scores on the questionnaire concerning QoL differed between
the four groups (see Table 3). Post hoc analysis showed a difference
between M-D and CD patients (p=0.01), with a higher perceived
physical QoL for the M-D patients (score of 50 vs. 44).
Univariate analysis of the whole dystonia group showed a negative
association between the QoL and almost all NMS (Supplementary
Table 5). Multivariate analysis in the whole dystonia group showed that
more fatigue (FSS) was associated with a lower physical QoL (β: -0.23,
p=0.00, Supplementary Table 6). More depressive and anxious
symptoms were associated with a lower mental QoL (β: -0.49, p= 0.00;
β: -0.42, p=0.00).
4. Discussion
To the best of our knowledge, this is the first study reporting on the
prevalence of NMS in M-D in direct comparison to other dystonia
subtypes. We found a high prevalence of psychiatric disorders in all
types of dystonia with more OCD and psychosis in M-D compared to CD
and DRD patients. Further, dystonia patients had more sleep problems
and fatigue than healthy controls. Compared to other dystonia sub-
types, M-D patients reported less excessive daytime sleepiness and fa-
tigue. QoL was lower in the dystonia groups compared to controls and
associated with NMS, showing that NMS are an important burden for
the dystonia patients.
Psychiatric co-morbidity was highly prevalent in the M-D group
with depressive disorder (36%), panic disorder (31%), agoraphobia
(28%) and OCD (19%) being most common. Previous studies reported a
comparable prevalence of these psychiatric disorders [3,5]. Conversely,
compared to previous studies we found a low rate (7%) of alcohol de-
pendence in our cohort [4,5]. We do not have a clear explanation for
this finding, perhaps this is due to a greater awareness of the risks of
alcohol dependence in M-D, or underreporting due to shameful feelings.
Compared to DRD and CD patients, in M-D patients we saw a higher
incidence of OCD and psychosis. Four M-D patients experienced some
features of psychosis (including auditory and/or visual hallucinations
and/or persecutory delusions) at some point in their lives. This rela-
tively high prevalence of psychosis in our cohort (10%) has only been
reported before in two M-D families [24,25]. Alterations of the dopa-
minergic signaling in the striatum are hypothesized to play a role in
developing psychosis, especially an imbalance between D2 and D1 re-
ceptors have been reported and blockage of D2 receptors with anti-
psychotic treatment is in some cases successful [26]. In M-D the do-
paminergic signaling in the striatum also plays a role, however, in a
SGCE knock out mouse model and in M-D patients a reduced radio-
tracer uptake of striatal D2 receptors was found [27]. Alterations in the
dopaminergic system are part of the pathophysiology of both psychosis
and M-D. This suggests that psychosis might be part of the phenotype of
M-D, however the underlying mechanisms need further study.
The relatively high prevalence of OCD in M-D is of special interest
because OCD is not considered to be a consequence of living with a
chronic disease. Although the precise pathophysiological pathways of
both M-D and OCD are not fully known, some similarities have been
suggested. Dysfunction of cortico-striatal connections is hypothesized
to be responsible for OCD [28], and an altered long-term depression of
the cortico-striatal synapses was found in a mouse model with a de-
creased expression of SGCE, representing M-D [2]. The globus pallidus
interna (GPi) is another structure of interest and plays a role in both the
pathophysiology of OCD and M-D. Successful deep brain stimulation
(DBS) of the GPi in patients with Tourette syndrome and OCD has been
described [29]. Similarly, GPi DBS has proven to be a successful
treatment in M-D and a previous study showed abnormal neuronal
activity in the GPi of M-D patients compared to other dystonias [30].
Another clue that OCD and M-D share a common pathway is the role of
mono-amine neurotransmitters, especially serotonin: in M-D, lower le-
vels of serotonin metabolites in CSF have been reported [31]. In OCD,
the serotonergic metabolism also plays a role, with selective serotonin
reuptake inhibitors being the first and most effective pharmacological
treatment option. The shared dysfunction in brain networks and the
mono-amine neurotransmitters dopamine and serotonin are highly
suggestive that NMS and motor symptoms in M-D have a common pa-
thophysiological pathway.
In our study we found an increased prevalence of anxiety disorders
in all dystonia patients compared to controls. The prevalence of gen-
eralized anxiety (47%) in the DRD group was even higher than in M-D
and CD patients. The serotonergic metabolism is also hypothesized to
play a role in both DRD and generalized anxiety. The impaired synth-
esis of tetrahydrobiopterin in DRD leads to an impaired synthesis of
other mono amines such as serotonin [32]. In generalized anxiety,
Table 3
Severity of psychiatric symptoms and sleep and fatigue.
M-D CD DRD p-value Controls p-value
Psychiatry N=40 N=51 N=18 N=53
BDI 7.5 (0–30) 8.0 (0–28) 5.0 (0–18) 0.067 2.5 (0–19) 0.000**
BAI 7.5 (0–42) 8.0 (1–31) 6.0 (0–31) 0.267 3.0 (0–21) 0.000**
YBOCS 0.0 (0–12) 0.0 (0–12) 0.0 (0–18) 0.917 0.0 (0–2) 0.074
Sleep N=40 N=44 N=19 N=46
ESS (SD) 7.3 (5.5) 8.8 (6.9) 12.1 (6.4) 0.030* 5.8 (4.9) 0.003**
FSS (SD) 35.0 (15.7) 39.6 (15.7) 36.9 (18.1) 0.425 24.0 (12.4) 0.000**
PSQI (SD) 5.9 (3.2) 7.4 (3.9) 8.9 (4.7) 0.016* 5.2 (4.3) 0.001**
Quality of Life N=41 N=51 N=19 N=52
QoL PC 50.0 (22–65) 44.3 (21–62) 49.0 (27–63) 0.010** 53.8 (26–62) 0.000**
QoL MC 46.8 (10–64) 48.4 (25–59) 50.0 (14–59) 0.520 55.5 (36–62) 0.000**
Values are presented as median (range) or as mean (SD) (as indicated). Kruskal wallis test or one way anova were performed to compare the three patient groups and
all four groups. BDI: Beck Depression Inventory; BAI:Beck Anxiety Inventory; YBOCS:Yale Brown Obsessive Compulsive Scale; ESS:Epworth Sleepiness Scale;
FSS:Fatigue Severity Scale; PSQI:Pittsburg Sleep Quality Index; QoL PC:physical component of quality of life; QoL MC:mental component of quality of life; M-
D:myoclonus dystonia; CD:cervical dystonia; DRD:dopa-responsive dystonia. *p < 0.05, **p < 0.01.
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disruption of the serotonergic system, especially the pathway leading
from the dorsal raphe nucleus via the amygdala to the frontal cortex, is
known to play a role [33]. Although DRD was not the primary focus of
our study, this further supports our hypothesis of a motor phenotype
specific psychiatric phenotype with different, dystonia-syndrome-spe-
cific pathophysiological pathways at play.
Apart from the psychiatric disorders, we found more fatigue in the
M-D group compared to controls, however, fatigue scores in the M-D
group were lower compared to the DRD patients. This might be due to
the dopaminergic medication but could also be explained by changes of
neurotransmitters in the basal ganglia, including serotonin and dopa-
mine which are suggested in fatigue [34]. Pathogenic variants in the
SGCE gene (M-D) and GCH1 gene (DRD) might influence these neuro-
transmitter pathways in a different way, leading to dystonia-specific
NMS.
Our study has some limitations: first, the sample sizes of our groups
were unequal. This unbalanced design was due to the rare nature of
especially DRD. Furthermore, the age of onset of the dystonia subtypes
was different in our cohort. Our analysis showed that age of onset in-
fluenced the odds ratio of OCD in M-D compared to CD patients. This
might have had some influence on our finding of significantly more
OCD in the M-D versus the CD patients. However, DRD patients have a
similar age of onset as M-D patients but have a prevalence of OCD that
is almost half the prevalence in M-D patients (11% vs. 20%). Another
limitation of this study is the lack of antidepressant treatment in the CD
group due to inclusion criteria of the previous study, which might have
underestimated the rate of psychiatric disorders in this group. Eight CD
patients were not included because they were using various anti-
depressants; and several additional patients were not asked to partici-
pate because of known medication use. The questionnaires about sleep
disorders and fatigue were not validated for use in dystonia patients.
However, they are widely used and the ESS and FSS are shown to have
good psychometric properties in dystonia patients [35,36]. In this
study, some NMS, including pain and cognitive problems, were not
assessed. Further studies are recommended to characterize these
symptoms in dystonia patients.
In conclusion, dystonia patients have a high incidence of NMS,
especially psychiatric features, sleep problems and fatigue, compared to
controls. More specifically, in M-D patients the prevalence of OCD and
psychosis is increased compared to CD and DRD patients, suggesting a
disease specific motor and non-motor phenotype. This is further sup-
ported by the relatively increased incidence of generalized anxiety in
DRD patients.
Further research is necessary to elucidate the underlying pathways,
with special attention for the involvement of neurotransmitters.
Clinicians should be aware of the psychiatric co-morbidity, sleep dis-
turbances and fatigue in dystonia in general, with a special focus on
OCD in M-D. The major influence of NMS on the QoL shows that NMS
are an important burden for dystonia patients and highlights the ne-
cessity of early recognition and treatment of the NMS. An increased
awareness for and personalized and adequate treatment of NMS might
lead to an improved QoL of the patients.
Funding
MT and ET received funding from the Dystonia Medical Research
Foundation (DMRF). DMRF had no involvement in study design, col-
lection, analysis and interpretation of data or writing of the report. All
other authors report no disclosures.
Data statement
The data that support the findings of this study are available from
the corresponding author, upon reasonable request.
Authors’ roles
ERT, MS, AK, ALB and MAJT contributed to the conception and
organization of the research project. ERT, MS, AK, ALB, SV, AMMS,
BAB and PS collected the data. ERT designed and executed the statis-
tical analysis, MS and MAJT reviewed the analysis. ERT, MS and MAJT
wrote the first draft of the article, all authors reviewed and edited the
final manuscript.
Declaration of competing interest
None.
Acknowledgment
The authors wish to acknowledge H. Eggink, J.M. Gelauff, J. C. van
Zijl and M.A. Coenen for assistance with collection of data, R. Zutt for
determining the severity of the motor symptoms for a part of the M-D
patients and R.E. Stewart for his assistance with statistical analysis.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.parkreldis.2019.10.015.
References
[1] K. Ritz, M.C. Gerrits, E.M. Foncke, F. van Ruissen, C. van der Linden,
M.D. Vergouwen, B.R. Bloem, W. Vandenberghe, R. Crols, J.D. Speelman, F. Baas,
M.A. Tijssen, Myoclonus-dystonia: clinical and genetic evaluation of a large cohort,
J. Neurol. Neurosurg. Psychiatry 80 (2009) 653–658, https://doi.org/10.1136/
jnnp.2008.162099.
[2] E. Roze, A.E. Lang, M. Vidailhet, Myoclonus-dystonia: classification, phenomen-
ology, pathogenesis, and treatment, Curr. Opin. Neurol. 31 (2018) 484–490,
https://doi.org/10.1097/WCO.0000000000000577.
[3] M.J. van Tricht, Y.E. Dreissen, D. Cath, J.M. Dijk, M.F. Contarino, S.M. van der
Salm, E.M. Foncke, J.L. Groen, B. Schmand, M.A. Tijssen, Cognition and psycho-
pathology in myoclonus-dystonia, J. Neurol. Neurosurg. Psychiatry 83 (2012)
814–820, https://doi.org/10.1136/jnnp-2011-301386.
[4] C.W. Hess, D. Raymond, C.A. Pde, S. Frucht, J. Shriberg, G.A. Heiman, R. Kurlan,
C. Klein, S.B. Bressman, L.J. Ozelius, R. Saunders-Pullman, Myoclonus-dystonia,
obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers,
Neurology 68 (2007) 522–524 doi:68/7/522 [pii].
[5] K.J. Peall, J.M. Dijk, R. Saunders-Pullman, Y.E. Dreissen, I. van Loon, D. Cath,
M.A. Kurian, M.J. Owen, E.M. Foncke, H.R. Morris, T. Gasser, S. Bressman,
F. Asmus, M.A. Tijssen, Psychiatric disorders, myoclonus dystonia and SGCE: an
international study, Ann. Clin. Transl. Neurol. 3 (2015) 4–11, https://doi.org/10.
1002/acn3.263.
[6] K.J. Peall, A. Kuiper, T.J. de Koning, M.A.J. Tijssen, Non-motor symptoms in ge-
netically defined dystonia: homogenous groups require systematic assessment,
Park. Relat. Disord. 21 (2015) 1031–1040, https://doi.org/10.1016/j.parkreldis.
2015.07.003.
[7] R. Lencer, S. Steinlechner, J. Stahlberg, H. Rehling, M. Orth, T. Baeumer,
H.J. Rumpf, C. Meyer, C. Klein, A. Muenchau, J. Hagenah, Primary focal dystonia:
evidence for distinct neuropsychiatric and personality profiles, J. Neurol.
Neurosurg. Psychiatry (2009), https://doi.org/10.1136/jnnp.2008.170191.
[8] M. Smit, A. Kuiper, V. Han, V.C. Jiawan, G. Douma, B. van Harten, J.M. Oen,
M.E. Pouwels, H.J. Dieks, A.L. Bartels, M.A. Tijssen, Psychiatric co-morbidity is
highly prevalent in idiopathic cervical dystonia and significantly influences health-
related quality of life: results of a controlled study, Park. Relat. Disord. 30 (2016)
7–12, https://doi.org/10.1016/j.parkreldis.2016.06.004.
[9] E.R. Timmers, A. Kuiper, M. Smit, A.L. Bartels, D.J. Kamphuis, N.I. Wolf, B.T. Poll-
The, T. Wassenberg, E.A.J. Peeters, T.J. de Koning, M.A.J. Tijssen, Non-motor
symptoms and quality of life in dopa-responsive dystonia patients, Park. Relat.
Disord. 45 (2017) 57–62, https://doi.org/10.1016/j.parkreldis.2017.10.005.
[10] G. Fabbrini, I. Berardelli, G. Moretti, M. Pasquini, M. Bloise, C. Colosimo, M. Biondi,
A. Berardelli, Psychiatric disorders in adult-onset focal dystonia: a case-control
study, Mov. Disord. 25 (2010) 459–465, https://doi.org/10.1002/mds.22983.
[11] M. Smit, A.S.J. Kamphuis, A.L. Bartels, V. Han, R.E. Stewart, I. Zijdewind,
M.A. Tijssen, Fatigue, sleep disturbances, and their influence on quality of life in
cervical dystonia patients, Mov. Disord. Clin. Pract. (2016), https://doi.org/10.
1002/mdc3.12459.
[12] W. Guy, The Clinical Global Impression Scale., ECDEU Assess. Man.
Psychopharmacol. US Dept. Heal. Educ. Welfare, ADAMHA, MIMH
Psychopharmacol. Res. Branch, Rockville, MD, 1976, pp. 218–222.
[13] R.E. Burke, S. Fahn, C.D. Marsden, S.B. Bressman, C. Moskowitz, J. Friedman,
Validity and reliability of a rating scale for the primary torsion dystonias, Neurology
E.R. Timmers, et al. Parkinsonism and Related Disorders 69 (2019) 85–90
89
35 (1985) 73–77.
[14] S.J. Frucht, S.E. Leurgans, M. Hallett, S. Fahn, The unified myoclonus rating scale,
Adv. Neurol. 89 (2002) 361–376.
[15] E.S. Consky, A.E. Lang, Clinical assessments of patients with cervical dystonia, in:
J. Jankovic, M. Hallett (Eds.), Ther. With Botulinum Toxin, NY Marcel Dekker, New
York, 1994, pp. 211–237.
[16] I.M. Van Vliet, H. Leroy, H. Van Megen, M.I.N.I. PLUS - M.I.N.I. International
Neuropsychiatric Interview, (2000) Nederlandse Version 5.0.0.
[17] A.T. Beck, A systematic investigation of depression, Compr. Psychiatr. 2 (1961)
163–170.
[18] A.T. Beck, N. Epstein, G. Brown, R.A. Steer, An inventory for measuring clinical
anxiety: psychometric properties, J. Consult. Clin. Psychol. 56 (1988) 893–897.
[19] W.K. Goodman, L.H. Price, S.A. Rasmussen, C. Mazure, R.L. Fleischmann, C.L. Hill,
G.R. Heninger, D.S. Charney, The Yale-Brown obsessive compulsive scale. I.
Development, use, and reliability, Arch. Gen. Psychiatr. 46 (1989) 1006–1011.
[20] D.J. Buysse, C.F.R. 3rd, T.H. Monk, S.R. Berman, D.J. Kupfer, The Pittsburgh Sleep
Quality Index: a new instrument for psychiatric practice and research, Psychiatry
Res. 28 (1989) 193–213 doi:0165-1781(89)90047-4 [pii].
[21] M.W. Johns, A new method for measuring daytime sleepiness: the Epworth slee-
piness scale, Sleep 14 (1991) 540–545.
[22] L.B. Krupp, N.G. LaRocca, J. Muir-Nash, A.D. Steinberg, The fatigue severity scale.
Application to patients with multiple sclerosis and systemic lupus erythematosus,
Arch. Neurol. 46 (1989) 1121–1123.
[23] K.I. VanderZee, R. Sanderman, J.W. Heyink, H. de Haes, Psychometric qualities of
the RAND 36-Item Health Survey 1.0: a multidimensional measure of general health
status, Int. J. Behav. Med. 3 (1996) 104–122, https://doi.org/10.1207/
s15327558ijbm0302_2.
[24] R.C. Dale, J.J. Nasti, G.B. Peters, Familial 7q21.3 microdeletion involving epsilon-
sarcoglycan causing myoclonus dystonia, cognitive impairment, and psychosis,
Mov. Disord. 26 (2011) 1774–1775, https://doi.org/10.1002/mds.23639.
[25] D.O. Doheny, M.F. Brin, C.E. Morrison, C.J. Smith, R.H. Walker, S. Abbasi,
B. Muller, J. Garrels, L. Liu, P.D.C. Aguiar, K. Schilling, P. Kramer, D. De Leon,
D. Raymond, R. Saunders-Pullman, C. Klein, S.B. Bressman, B. Schmand,
M.A. Tijssen, L.J. Ozelius, J.M. Silverman, Phenotypic features of myoclonus-dys-
tonia in three kindreds, Neurology 59 (2002) 1187–1196.
[26] J.P. Kesby, D.W. Eyles, J.J. McGrath, J.G. Scott, Dopamine, psychosis and schizo-
phrenia: the widening gap between basic and clinical neuroscience, Transl.
Psychiatry 8 (2018) 30, https://doi.org/10.1038/s41398-017-0071-9.
[27] L. Zhang, F. Yokoi, D.S. Parsons, D.G. Standaert, Y. Li, Alteration of striatal dopa-
minergic neurotransmission in a mouse model of DYT11 myoclonus-dystonia, PLoS
One 7 (2012) e33669, , https://doi.org/10.1371/journal.pone.0033669.
[28] D.A. Drubach, Obsessive-compulsive disorder, Continuum 21 (2015) 783–788,
https://doi.org/10.1212/01.CON.0000466666.12779.07.
[29] G. Nair, A. Evans, R.E. Bear, D. Velakoulis, R.G. Bittar, The anteromedial GPi as a
new target for deep brain stimulation in obsessive compulsive disorder, J. Clin.
Neurosci. 21 (2014) 815–821, https://doi.org/10.1016/j.jocn.2013.10.003.
[30] M.-L. Welter, D. Grabli, C. Karachi, N. Jodoin, S. Fernandez-Vidal, Y. Brun,
S. Navarro, A. Rogers, P. Cornu, B. Pidoux, J. Yelnik, E. Roze, E. Bardinet,
M. Vidailhet, Pallidal activity in myoclonus dystonia correlates with motor signs,
Mov. Disord. 30 (2015) 992–996, https://doi.org/10.1002/mds.26244.
[31] K.J. Peall, J. Ng, M.E. Dy, N. Sharma, S. Pope, S. Heales, J.R. Friedman,
M.A. Kurian, Low CSF 5-HIAA in myoclonus dystonia, Mov. Disord. 32 (2017)
1647–1649, https://doi.org/10.1002/mds.27117.
[32] Y. Furukawa, GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia, (2015)
GeneReviews [online].
[33] D.J. Nutt, Neurobiological mechanisms in generalized anxiety disorder, J. Clin.
Psychiatry 62 (Suppl 11) (2001) 22–7; discussion 28.
[34] A. Chaudhuri, P.O. Behan, Fatigue and basal ganglia, J. Neurol. Sci. 179 (2000)
34–42.
[35] M.M. Kurtis, R. Balestrino, C. Rodriguez-Blazquez, M.J. Forjaz, P. Martinez-Martin,
A review of scales to evaluate sleep disturbances in movement disorders, Front.
Neurol. 9 (2018) 369.
[36] A.W. Shukla, R. Brown, K. Heese, J. Jones, R.L. Rodriguez, I.M. Malaty, M.S. Okun,
B.M. Kluger, High rates of fatigue and sleep disturbances in dystonia, Int. J.
Neurosci. (2015) 1–8, https://doi.org/10.3109/00207454.2015.1085035.
E.R. Timmers, et al. Parkinsonism and Related Disorders 69 (2019) 85–90
90
